NR 547 CEA Exam ACTUAL EXAM
2026/2027 | Chamberlain Pre-Clinical
Diagnostic | 75 Questions | Verified Q&A |
Pass Guaranteed - A+ Graded
Section 1: Neurobiology & Psychopharmacology (Questions 1–10)
Q1: A 34-year-old patient with major depressive disorder is started on sertraline 50 mg daily. After 2
weeks, the patient reports improved sleep and appetite but no change in depressed mood. The PMHNP
explains that the delayed antidepressant effect is due to which neurobiological mechanism?
A. Immediate downregulation of postsynaptic 5-HT1A autoreceptors causing rapid synaptic serotonin
increase
B. Gradual desensitization of somatodendritic 5-HT1A autoreceptors, leading to enhanced serotonergic
neurotransmission over 4–6 weeks [CORRECT]
C. Direct antagonism of NMDA receptors resulting in immediate synaptic plasticity changes
D. Rapid inhibition of serotonin reuptake with immediate downstream BDNF release in the hippocampus
Correct Answer: B
Rationale: The therapeutic lag in SSRI response (2–4+ weeks) is attributed to gradual desensitization of
somatodendritic 5-HT1A autoreceptors in the raphe nuclei. Initially, increased synaptic serotonin
stimulates these autoreceptors, reducing firing rate; chronic SSRI use desensitizes them, restoring and
enhancing serotonergic transmission. While NMDA antagonism (C) relates to ketamine's rapid
mechanism, not standard SSRIs. The 5-HT1A autoreceptor desensitization timeline matches the clinical
observation of early somatic symptom improvement (sleep/appetite) before mood elevation.
Q2: A patient with bipolar I disorder is prescribed lithium carbonate. Which pharmacokinetic
characteristic requires the most careful monitoring in a 68-year-old patient with decreased renal
function?
A. Lithium is metabolized by CYP2D6, requiring dose adjustment with aging hepatic blood flow
B. Lithium follows zero-order kinetics, making dosing unpredictable regardless of renal function
,C. Lithium is entirely renally excreted unchanged with a narrow therapeutic index; age-related GFR
reduction increases toxicity risk [CORRECT]
D. Lithium undergoes extensive first-pass hepatic metabolism, requiring higher oral doses in elderly
patients
Correct Answer: C
Rationale: Lithium is filtered at the glomerulus and reabsorbed in the proximal tubule (competing with
sodium), with no hepatic metabolism. Its therapeutic index is narrow (0.6–1.2 mEq/L), and age-
associated GFR decline significantly increases accumulation and neurotoxicity risk. While CYP2D6 (A) is
irrelevant to lithium, and first-pass metabolism (D) does not occur. Lithium follows first-order, not zero-
order (B), kinetics at therapeutic doses.
Q3: A 29-year-old with schizophrenia is prescribed risperidone 4 mg daily. The patient develops
amenorrhea and galactorrhea. Which receptor mechanism explains these adverse effects?
A. Antagonism of D2 receptors in the tuberoinfundibular pathway, disinhibiting prolactin release
[CORRECT]
B. Antagonism of 5-HT2A receptors in the hypothalamus, disrupting GnRH pulsatility
C. Agonism of D2 receptors in the mesolimbic pathway, stimulating prolactin inhibitory factor
D. Blockade of muscarinic M3 receptors in the anterior pituitary, preventing prolactin suppression
Correct Answer: A
Rationale: D2 receptor antagonism in the tuberoinfundibular pathway (hypothalamus to anterior
pituitary) removes tonic inhibition of prolactin release, causing hyperprolactinemia. Risperidone's
potent D2 blockade (and poor blood-brain barrier penetration of this pathway) makes it particularly
prone to this effect. While 5-HT2A antagonism (B) characterizes atypical antipsychotics' reduced EPS, it
does not explain prolactin elevation. D2 agonism (C) would decrease prolactin, and M3 blockade (D)
relates to metabolic effects, not prolactin.
Q4: A patient with generalized anxiety disorder is started on buspirone. The PMHNP counsels the
patient that onset of anxiolytic effect may take 2–3 weeks. This delayed onset is primarily due to which
mechanism?
A. Buspirone requires accumulation in adipose tissue before reaching therapeutic CNS levels
B. Partial agonism at 5-HT1A postsynaptic receptors requires adaptive neuronal changes for clinical
effect [CORRECT]
C. Buspirone is a prodrug requiring hepatic conversion to its active metabolite 1-PP
D. The drug must first downregulate GABA-A benzodiazepine receptors to exert anxiolysis
,Correct Answer: B
Rationale: Buspirone is a partial agonist at 5-HT1A postsynaptic receptors and full agonist at
somatodendritic autoreceptors. Its anxiolytic effect requires time-dependent adaptive changes in
serotonergic neurotransmission similar to SSRIs, not immediate GABA modulation. Buspirone is not a
prodrug (C)—1-PP is an active metabolite but not the primary mechanism. It does not act via GABA-A
receptors (D) or accumulate in fat (A).
Q5: A 42-year-old patient with treatment-resistant depression is being considered for adjunctive
aripiprazole to sertraline. The proposed mechanism of antidepressant augmentation involves:
A. Pure D2 receptor antagonism, enhancing mesolimbic dopamine for pleasure/reward
B. 5-HT2A antagonism with D2 partial agonism, stabilizing dopaminergic and serotonergic tone
[CORRECT]
C. Norepinephrine reuptake inhibition combined with direct 5-HT1A full agonism
D. NMDA receptor antagonism with rapid synaptic glutamate surge
Correct Answer: B
Rationale: Aripiprazole's antidepressant augmentation mechanism involves partial D2 agonism
(stabilizing dopamine in low-tone states without excessive blockade) and 5-HT2A antagonism
(enhancing frontocortical dopamine and serotonin release). This "dopamine-serotonin system stabilizer"
profile distinguishes it from full D2 antagonists. NMDA antagonism (D) describes esketamine, and
aripiprazole lacks significant norepinephrine reuptake inhibition (C).
Q6: A patient on valproic acid for bipolar disorder presents with tremor, confusion, and elevated
ammonia levels. The most likely mechanism is:
A. Direct hepatotoxicity causing acute hepatic failure and hepatic encephalopathy
B. Inhibition of carbamoyl phosphate synthetase I, impairing urea cycle metabolism and causing
hyperammonemia [CORRECT]
C. Idiosyncratic bone marrow suppression leading to hypoxia and metabolic encephalopathy
D. Competitive inhibition of GABA transaminase causing excessive GABA accumulation
Correct Answer: B
Rationale: Valproate inhibits carbamoyl phosphate synthetase I, the first enzyme in the urea cycle,
causing hyperammonemia encephalopathy independent of hepatic dysfunction (though hepatotoxicity
can co-occur). This is a dose-dependent, reversible metabolic effect. While valproate does inhibit GABA
transaminase (D), this mechanism increases GABA and does not explain ammonia elevation. Bone
marrow suppression (C) is unrelated to ammonia.
, Q7: Which pharmacodynamic property best explains why clozapine is effective for treatment-resistant
schizophrenia while carrying the lowest risk of extrapyramidal symptoms?
A. Highest D2 receptor occupancy (>90%) combined with potent muscarinic agonism
B. Rapid dissociation from D2 receptors (fast off-rate) with broad receptor profile including 5-HT2A
antagonism [CORRECT]
C. Selective D3 receptor antagonism with minimal striatal D2 binding
D. Pure 5-HT1A agonism without any dopamine receptor interaction
Correct Answer: B
Rationale: Clozapine's "fast off-rate" D2 dissociation (transient, loose binding) allows physiological
dopamine surges to compete, preventing sustained receptor blockade and EPS. Combined with potent
5-HT2A antagonism (increasing dopamine release in nigrostriatal pathway), this creates a favorable
antipsychotic/EPS ratio. D2 occupancy is actually relatively low (~50-60%) compared to other
antipsychotics. D3 antagonism (C) and pure 5-HT1A agonism (D) do not characterize clozapine.
Q8: A patient with panic disorder is prescribed venlafaxine XR. The mechanism by which SNRIs reduce
panic attacks involves:
A. Immediate enhancement of GABAergic inhibition in the amygdala via noradrenergic modulation
B. Increased serotonergic tone in the periaqueductal gray and locus coeruleus noradrenergic
stabilization [CORRECT]
C. Direct antagonism of CCK-B receptors in the hypothalamus preventing panic provocation
D. Rapid induction of neurogenesis in the basolateral amygdala via BDNF-mediated TrkB signaling
Correct Answer: B
Rationale: Panic disorder pathophysiology involves dysregulated serotonergic input to the
periaqueductal gray (PAG) and excessive locus coeruleus noradrenergic firing. SNRIs enhance
serotonergic inhibition of the PAG (reducing "flight" responses) and stabilize noradrenergic tone. While
BDNF/neurogenesis (D) occurs with chronic antidepressant use, it is not the primary panic-specific
mechanism. SNRIs do not act via GABA (A) or CCK-B receptors (C).
Q9: A patient on long-term haloperidol develops tardive dyskinesia. The proposed pathophysiology
involves:
A. Excessive GABAergic inhibition in the indirect pathway leading to thalamic hyperactivation
B. D2 receptor supersensitivity in the nigrostriatal pathway due to chronic antagonism and upregulation
[CORRECT]
2026/2027 | Chamberlain Pre-Clinical
Diagnostic | 75 Questions | Verified Q&A |
Pass Guaranteed - A+ Graded
Section 1: Neurobiology & Psychopharmacology (Questions 1–10)
Q1: A 34-year-old patient with major depressive disorder is started on sertraline 50 mg daily. After 2
weeks, the patient reports improved sleep and appetite but no change in depressed mood. The PMHNP
explains that the delayed antidepressant effect is due to which neurobiological mechanism?
A. Immediate downregulation of postsynaptic 5-HT1A autoreceptors causing rapid synaptic serotonin
increase
B. Gradual desensitization of somatodendritic 5-HT1A autoreceptors, leading to enhanced serotonergic
neurotransmission over 4–6 weeks [CORRECT]
C. Direct antagonism of NMDA receptors resulting in immediate synaptic plasticity changes
D. Rapid inhibition of serotonin reuptake with immediate downstream BDNF release in the hippocampus
Correct Answer: B
Rationale: The therapeutic lag in SSRI response (2–4+ weeks) is attributed to gradual desensitization of
somatodendritic 5-HT1A autoreceptors in the raphe nuclei. Initially, increased synaptic serotonin
stimulates these autoreceptors, reducing firing rate; chronic SSRI use desensitizes them, restoring and
enhancing serotonergic transmission. While NMDA antagonism (C) relates to ketamine's rapid
mechanism, not standard SSRIs. The 5-HT1A autoreceptor desensitization timeline matches the clinical
observation of early somatic symptom improvement (sleep/appetite) before mood elevation.
Q2: A patient with bipolar I disorder is prescribed lithium carbonate. Which pharmacokinetic
characteristic requires the most careful monitoring in a 68-year-old patient with decreased renal
function?
A. Lithium is metabolized by CYP2D6, requiring dose adjustment with aging hepatic blood flow
B. Lithium follows zero-order kinetics, making dosing unpredictable regardless of renal function
,C. Lithium is entirely renally excreted unchanged with a narrow therapeutic index; age-related GFR
reduction increases toxicity risk [CORRECT]
D. Lithium undergoes extensive first-pass hepatic metabolism, requiring higher oral doses in elderly
patients
Correct Answer: C
Rationale: Lithium is filtered at the glomerulus and reabsorbed in the proximal tubule (competing with
sodium), with no hepatic metabolism. Its therapeutic index is narrow (0.6–1.2 mEq/L), and age-
associated GFR decline significantly increases accumulation and neurotoxicity risk. While CYP2D6 (A) is
irrelevant to lithium, and first-pass metabolism (D) does not occur. Lithium follows first-order, not zero-
order (B), kinetics at therapeutic doses.
Q3: A 29-year-old with schizophrenia is prescribed risperidone 4 mg daily. The patient develops
amenorrhea and galactorrhea. Which receptor mechanism explains these adverse effects?
A. Antagonism of D2 receptors in the tuberoinfundibular pathway, disinhibiting prolactin release
[CORRECT]
B. Antagonism of 5-HT2A receptors in the hypothalamus, disrupting GnRH pulsatility
C. Agonism of D2 receptors in the mesolimbic pathway, stimulating prolactin inhibitory factor
D. Blockade of muscarinic M3 receptors in the anterior pituitary, preventing prolactin suppression
Correct Answer: A
Rationale: D2 receptor antagonism in the tuberoinfundibular pathway (hypothalamus to anterior
pituitary) removes tonic inhibition of prolactin release, causing hyperprolactinemia. Risperidone's
potent D2 blockade (and poor blood-brain barrier penetration of this pathway) makes it particularly
prone to this effect. While 5-HT2A antagonism (B) characterizes atypical antipsychotics' reduced EPS, it
does not explain prolactin elevation. D2 agonism (C) would decrease prolactin, and M3 blockade (D)
relates to metabolic effects, not prolactin.
Q4: A patient with generalized anxiety disorder is started on buspirone. The PMHNP counsels the
patient that onset of anxiolytic effect may take 2–3 weeks. This delayed onset is primarily due to which
mechanism?
A. Buspirone requires accumulation in adipose tissue before reaching therapeutic CNS levels
B. Partial agonism at 5-HT1A postsynaptic receptors requires adaptive neuronal changes for clinical
effect [CORRECT]
C. Buspirone is a prodrug requiring hepatic conversion to its active metabolite 1-PP
D. The drug must first downregulate GABA-A benzodiazepine receptors to exert anxiolysis
,Correct Answer: B
Rationale: Buspirone is a partial agonist at 5-HT1A postsynaptic receptors and full agonist at
somatodendritic autoreceptors. Its anxiolytic effect requires time-dependent adaptive changes in
serotonergic neurotransmission similar to SSRIs, not immediate GABA modulation. Buspirone is not a
prodrug (C)—1-PP is an active metabolite but not the primary mechanism. It does not act via GABA-A
receptors (D) or accumulate in fat (A).
Q5: A 42-year-old patient with treatment-resistant depression is being considered for adjunctive
aripiprazole to sertraline. The proposed mechanism of antidepressant augmentation involves:
A. Pure D2 receptor antagonism, enhancing mesolimbic dopamine for pleasure/reward
B. 5-HT2A antagonism with D2 partial agonism, stabilizing dopaminergic and serotonergic tone
[CORRECT]
C. Norepinephrine reuptake inhibition combined with direct 5-HT1A full agonism
D. NMDA receptor antagonism with rapid synaptic glutamate surge
Correct Answer: B
Rationale: Aripiprazole's antidepressant augmentation mechanism involves partial D2 agonism
(stabilizing dopamine in low-tone states without excessive blockade) and 5-HT2A antagonism
(enhancing frontocortical dopamine and serotonin release). This "dopamine-serotonin system stabilizer"
profile distinguishes it from full D2 antagonists. NMDA antagonism (D) describes esketamine, and
aripiprazole lacks significant norepinephrine reuptake inhibition (C).
Q6: A patient on valproic acid for bipolar disorder presents with tremor, confusion, and elevated
ammonia levels. The most likely mechanism is:
A. Direct hepatotoxicity causing acute hepatic failure and hepatic encephalopathy
B. Inhibition of carbamoyl phosphate synthetase I, impairing urea cycle metabolism and causing
hyperammonemia [CORRECT]
C. Idiosyncratic bone marrow suppression leading to hypoxia and metabolic encephalopathy
D. Competitive inhibition of GABA transaminase causing excessive GABA accumulation
Correct Answer: B
Rationale: Valproate inhibits carbamoyl phosphate synthetase I, the first enzyme in the urea cycle,
causing hyperammonemia encephalopathy independent of hepatic dysfunction (though hepatotoxicity
can co-occur). This is a dose-dependent, reversible metabolic effect. While valproate does inhibit GABA
transaminase (D), this mechanism increases GABA and does not explain ammonia elevation. Bone
marrow suppression (C) is unrelated to ammonia.
, Q7: Which pharmacodynamic property best explains why clozapine is effective for treatment-resistant
schizophrenia while carrying the lowest risk of extrapyramidal symptoms?
A. Highest D2 receptor occupancy (>90%) combined with potent muscarinic agonism
B. Rapid dissociation from D2 receptors (fast off-rate) with broad receptor profile including 5-HT2A
antagonism [CORRECT]
C. Selective D3 receptor antagonism with minimal striatal D2 binding
D. Pure 5-HT1A agonism without any dopamine receptor interaction
Correct Answer: B
Rationale: Clozapine's "fast off-rate" D2 dissociation (transient, loose binding) allows physiological
dopamine surges to compete, preventing sustained receptor blockade and EPS. Combined with potent
5-HT2A antagonism (increasing dopamine release in nigrostriatal pathway), this creates a favorable
antipsychotic/EPS ratio. D2 occupancy is actually relatively low (~50-60%) compared to other
antipsychotics. D3 antagonism (C) and pure 5-HT1A agonism (D) do not characterize clozapine.
Q8: A patient with panic disorder is prescribed venlafaxine XR. The mechanism by which SNRIs reduce
panic attacks involves:
A. Immediate enhancement of GABAergic inhibition in the amygdala via noradrenergic modulation
B. Increased serotonergic tone in the periaqueductal gray and locus coeruleus noradrenergic
stabilization [CORRECT]
C. Direct antagonism of CCK-B receptors in the hypothalamus preventing panic provocation
D. Rapid induction of neurogenesis in the basolateral amygdala via BDNF-mediated TrkB signaling
Correct Answer: B
Rationale: Panic disorder pathophysiology involves dysregulated serotonergic input to the
periaqueductal gray (PAG) and excessive locus coeruleus noradrenergic firing. SNRIs enhance
serotonergic inhibition of the PAG (reducing "flight" responses) and stabilize noradrenergic tone. While
BDNF/neurogenesis (D) occurs with chronic antidepressant use, it is not the primary panic-specific
mechanism. SNRIs do not act via GABA (A) or CCK-B receptors (C).
Q9: A patient on long-term haloperidol develops tardive dyskinesia. The proposed pathophysiology
involves:
A. Excessive GABAergic inhibition in the indirect pathway leading to thalamic hyperactivation
B. D2 receptor supersensitivity in the nigrostriatal pathway due to chronic antagonism and upregulation
[CORRECT]
